Literature DB >> 32057679

Airway profile of bioactive lipids predicts early progression of lung disease in cystic fibrosis.

Hamed Horati1, Hettie M Janssens1, Camilla Margaroli2, Mieke Veltman3, Marta Stolarczyk4, Matthew B Kilgore2, Jeffrey Chou2, Limin Peng5, Harm A M W Tiddens1, Joshua D Chandler2, Rabindra Tirouvanziam2, Bob J Scholte6.   

Abstract

BACKGROUND: Previously, we showed that abnormal levels of bioactive lipids in bronchoalveolar lavage fluid (BALF) from infants with cystic fibrosis (CF) correlated with early structural lung damage.
METHOD: To extend these studies, BALF bioactive lipid measurement by mass spectrometry and chest computed tomography (CT, combined with the sensitive PRAGMA-CF scoring method) were performed longitudinally at 2-year intervals in a new cohort of CF children (n = 21, aged 1-5 yrs).
RESULTS: PRAGMA-CF, neutrophil elastase activity, and myeloperoxidase correlated with BALF lysolipids and isoprostanes, markers of oxidative stress, as well as prostaglandin E2 and combined ceramide precursors (Spearman's Rho > 0.5; P < 0.01 for all). Multiple protein agonists of inflammation and tissue remodeling, measured by Olink protein array, correlated positively (r = 0.44-0.79, p < 0.05) with PRAGMA-CF scores and bioactive lipid levels. Notably, levels of lysolipids, prostaglandin E2 and isoprostanes at first BALF predicted the evolution of PRAGMA-CF scores 2 years later. In wild-type differentiated primary bronchial epithelial cells, and in CFTR-inducible iCFBE cells, treatment with a lysolipid receptor agonist (VPC3114) enhanced shedding of pro-inflammatory and pro-fibrotic proteins.
CONCLUSIONS: Together, our findings suggest that bioactive lipids in BALF correlate with and possibly predict structural lung disease in CF children, which supports their use as biomarkers of disease progression and treatment efficacy. Furthermore, our data suggest a causative role of airway lysolipids and oxidative stress in the progression of early CF lung disease, unveiling potential therapeutic targets.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  ADAM17; Amphiregulin; EGFR; Lysolipid receptor; Lysophosphatidic acid; Oxidative stress

Year:  2020        PMID: 32057679      PMCID: PMC7415592          DOI: 10.1016/j.jcf.2020.01.010

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  20 in total

Review 1.  Principal component analysis and exploratory factor analysis.

Authors:  I T Joliffe; B J Morgan
Journal:  Stat Methods Med Res       Date:  1992       Impact factor: 3.021

2.  PRAGMA-CF. A Quantitative Structural Lung Disease Computed Tomography Outcome in Young Children with Cystic Fibrosis.

Authors:  Tim Rosenow; Merel C J Oudraad; Conor P Murray; Lidija Turkovic; Wieying Kuo; Marleen de Bruijne; Sarath C Ranganathan; Harm A W M Tiddens; Stephen M Stick
Journal:  Am J Respir Crit Care Med       Date:  2015-05-15       Impact factor: 21.405

3.  Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme: evidence from bench to bedside.

Authors:  Dušan Garić; Juan B De Sanctis; Gabriella Wojewodka; Daniel Houle; Shanon Cupri; Asmahan Abu-Arish; John W Hanrahan; Marian Hajduch; Elias Matouk; Danuta Radzioch
Journal:  J Mol Med (Berl)       Date:  2017-07-10       Impact factor: 4.599

4.  Lysophosphatidic acid receptor 1 modulates lipopolysaccharide-induced inflammation in alveolar epithelial cells and murine lungs.

Authors:  Jing Zhao; Donghong He; Yanlin Su; Evgeny Berdyshev; Jerold Chun; Viswanathan Natarajan; Yutong Zhao
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-08-05       Impact factor: 5.464

Review 5.  Biochemistry of very-long-chain and long-chain ceramides in cystic fibrosis and other diseases: The importance of side chain.

Authors:  Dušan Garić; Juan B De Sanctis; Juhi Shah; Daciana Catalina Dumut; Danuta Radzioch
Journal:  Prog Lipid Res       Date:  2019-03-12       Impact factor: 16.195

6.  Lysophosphatidic acid increases phosphatidic acid formation, phospholipase D activity and degranulation by human neutrophils.

Authors:  Jen-Sie Tou; Jacquelyn S Gill
Journal:  Cell Signal       Date:  2005-01       Impact factor: 4.315

7.  Lack of Sphingosine Causes Susceptibility to Pulmonary Staphylococcus Aureus Infections in Cystic Fibrosis.

Authors:  Shaghayegh Tavakoli Tabazavareh; Aaron Seitz; Peter Jernigan; Carolin Sehl; Simone Keitsch; Stephan Lang; Barbara C Kahl; Michael Edwards; Heike Grassmé; Erich Gulbins; Katrin Anne Becker
Journal:  Cell Physiol Biochem       Date:  2016-05-17

8.  Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia.

Authors:  Guido Veit; Florian Bossard; Julie Goepp; A S Verkman; Luis J V Galietta; John W Hanrahan; Gergely L Lukacs
Journal:  Mol Biol Cell       Date:  2012-09-12       Impact factor: 4.138

9.  Infection Is Not Required for Mucoinflammatory Lung Disease in CFTR-Knockout Ferrets.

Authors:  Bradley H Rosen; T Idil Apak Evans; Shashanna R Moll; Jaimie S Gray; Bo Liang; Xingshen Sun; Yulong Zhang; Chandler W Jensen-Cody; Anthony M Swatek; Weihong Zhou; Nan He; Pavana G Rotti; Scott R Tyler; Nicholas W Keiser; Preston J Anderson; Leonard Brooks; Yalan Li; R Marshall Pope; Maheen Rajput; Eric A Hoffman; Kai Wang; J Kirk Harris; Kalpaj R Parekh; Katherine N Gibson-Corley; John F Engelhardt
Journal:  Am J Respir Crit Care Med       Date:  2018-05-15       Impact factor: 30.528

10.  Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability.

Authors:  Erika Assarsson; Martin Lundberg; Göran Holmquist; Johan Björkesten; Stine Bucht Thorsen; Daniel Ekman; Anna Eriksson; Emma Rennel Dickens; Sandra Ohlsson; Gabriella Edfeldt; Ann-Catrin Andersson; Patrik Lindstedt; Jan Stenvang; Mats Gullberg; Simon Fredriksson
Journal:  PLoS One       Date:  2014-04-22       Impact factor: 3.240

View more
  3 in total

Review 1.  Cystic Fibrosis Lung Disease in the Aging Population.

Authors:  Lisa Künzi; Molly Easter; Meghan June Hirsch; Stefanie Krick
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 2.  CFTR Protein: Not Just a Chloride Channel?

Authors:  Laurence S Hanssens; Jean Duchateau; Georges J Casimir
Journal:  Cells       Date:  2021-10-22       Impact factor: 6.600

Review 3.  Glycosaminoglycans as Multifunctional Anti-Elastase and Anti-Inflammatory Drugs in Cystic Fibrosis Lung Disease.

Authors:  Judith A Voynow; Shuo Zheng; Apparao B Kummarapurugu
Journal:  Front Pharmacol       Date:  2020-07-08       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.